Document is current

Article History

Received: 20 May 2023

Accepted: 13 October 2023

First Online: 14 December 2023

Declarations

:

: The study was approved by the Ethics Committee of the Goethe-University Frankfurt. Informed consent was waived due to the retrospective nature of the study. We adhered to the Strengthening Reporting of Observational Studies in Epidemiology (STROBE) guidelines [].

: Not applicable.

: LM reports speakers’ Honoria from Eisai. FR and AS are members of the editorial board of Neurological Research and Practice. FR reports personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals/Jazz Pharma, Roche Pharma, and UCB Pharma, and grants from the Detlev–Wrobel–Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Marinus Pharma, Precisis, UCB, UNEEG medical, and Zogenix. KW was supported by the Mildred Scheel Career Center Frankfurt, funded by Deutsche Krebshilfe. CM reports speakers’ honoraria from Eisai and travel support from GW Pharmaceuticals. LMW, PH and EH report no conflicts of interest.